- Home
- BDRX vs PRPO Comparison
BDRX vs PRPO Comparison
Compare BDRX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- PRPO
- Stock Information
- Founded
- BDRX 2000
- PRPO N/A
- Country
- BDRX United Kingdom
- PRPO United States
- Employees
- BDRX N/A
- PRPO N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- BDRX Health Care
- PRPO Industrials
- Exchange
- BDRX Nasdaq
- PRPO Nasdaq
- Market Cap
- BDRX 2.8M
- PRPO 9.6M
- IPO Year
- BDRX N/A
- PRPO N/A
- Fundamental
- Price
- BDRX $5.98
- PRPO $6.70
- Analyst Decision
- BDRX Strong Buy
- PRPO
- Analyst Count
- BDRX 1
- PRPO 0
- Target Price
- BDRX $200.00
- PRPO N/A
- AVG Volume (30 Days)
- BDRX 455.7K
- PRPO 7.7K
- Earning Date
- BDRX 10-29-2024
- PRPO 11-11-2024
- Dividend Yield
- BDRX N/A
- PRPO N/A
- EPS Growth
- BDRX N/A
- PRPO N/A
- EPS
- BDRX N/A
- PRPO N/A
- Revenue
- BDRX $104,895.00
- PRPO $16,719,999.00
- Revenue This Year
- BDRX N/A
- PRPO $75.18
- Revenue Next Year
- BDRX N/A
- PRPO N/A
- P/E Ratio
- BDRX N/A
- PRPO N/A
- Revenue Growth
- BDRX N/A
- PRPO 52.61
- 52 Week Low
- BDRX $4.71
- PRPO $4.31
- 52 Week High
- BDRX $220.25
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- BDRX 42.77
- PRPO 52.82
- Support Level
- BDRX $5.50
- PRPO $6.42
- Resistance Level
- BDRX $10.89
- PRPO $6.99
- Average True Range (ATR)
- BDRX 1.13
- PRPO 0.33
- MACD
- BDRX 0.31
- PRPO -0.04
- Stochastic Oscillator
- BDRX 20.55
- PRPO 69.91
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.